Chengzhi Y. Lu

No. 24, Fukang Road, 
Tianjin, CN 
Clinical Trials:Currently Recruiting for 1 Trial
No. 24, Fukang Road, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Chengzhi Lu practices in Tianjin, China. Their top areas of expertise are Cerebral Hypoxia, Biliary Hypoplasia, Heart Attack, Percutaneous Coronary Intervention (PCI), and Cardiac Ablation.

Their clinical research consists of co-authoring 89 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 24, Fukang Road, Tianjin, 300192, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Enrollment Status: Recruiting
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: rhNRG-1
Study Phase: Phase 3
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
View 1 Less Clinical Trial

89 Total Publications

Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis.
Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis.
Journal: Basic research in cardiology
Published: April 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lu's expertise for a condition
ConditionClose
        View All 24 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile